• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)

    5/21/24 8:03:23 PM ET
    $CLVR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVR alert in real time by email
    SC 13D/A 1 tm2415063d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Clever Leaves Holdings Inc.

     

     

    (Name of Issuer)

     

    Common Shares, without par value
     

     

    (Title of Class of Securities)

     

    186760203
     

     

    (CUSIP Number of Class of Securities)

     

    BCM Investimentos Fundo de Investimento
    Multimercado Crédito Privado Investimento no Exterior

    B.Side Wealth Management Gestão de Recursos Ltda.
    Antonio Costa

    Martim Prado Mattos

    Rua Joaquim Floriano, 960

    17th Floor, Itaim Bibi

    São Paulo, SP. Brazil. 04534-004
    +55 11 4502 1234

     

     

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    May 16, 2024

     

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  186760203   Page 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    BCM Investimentos Fundo de Investimento Multimercado Crédito Privado Investimento no Exterior

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Brazil

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    322,236

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    322,236

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    322,236

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    18.36%1

    14

    TYPE OF REPORTING PERSON (See Instructions)

    IV

               

     
    1Based on 1,754,795 Shares outstanding as of March 19, 2024, as disclosed in the Annual Report on Form 10-K filed by the Issuer with the SEC on April 1, 2024 (the “Form 10-K”).

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  186760203   Page 3 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    B.Side Wealth Management Gestão de Recursos Ltda.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

    OO; AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Brazil

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    322,236

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    322,236

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    322,236

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    18.36%2

    14

    TYPE OF REPORTING PERSON (See Instructions)

    IA; OO

               

     
    2Based on 1,754,795 Shares outstanding as of March 19, 2024, as disclosed in the Form 10-K.

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  186760203   Page 4 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Antonio Costa

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Brazil

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    322,236

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    322,236

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    322,236

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    18.36%3

    14

    TYPE OF REPORTING PERSON (See Instructions)

    IN; OO

               

     
    3Based on 1,754,795 Shares outstanding as of March 19, 2024, as disclosed in the Form 10-K.

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  186760203   Page 5 of 9 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Martim Prado Mattos

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Brazil

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    322,236

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    322,236

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    322,236

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    18.36%4

    14

    TYPE OF REPORTING PERSON (See Instructions)

    IN; OO

               

     

    4Based on 1,754,795 Shares outstanding as of March 19, 2024, as disclosed in the Form 10-K.

     

     

     

    AMENDMENT NO. 1 TO SCHEDULE 13D

     

    This Amendment No. 1 (this “Amendment”) amends the Statement on Schedule 13D, filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2024 (the “Original Statement”; as amended by this Amendment, this “Statement”), with respect to the common shares, without par value (the “Shares”), of Clever Leaves Holdings, Inc., a corporation organized under the laws of the province of British Columbia under the Business Corporations Act (British Columbia) (the “Issuer”). Capitalized terms used herein but not defined have the respective meanings ascribed to them in the Original Statement.

     

    ITEM 3.Source and Amount of Funds or Other Consideration

     

    Item 3 of the Statement is hereby amended and supplemented by the addition of the following information:

     

    On May 16, 2024, BCM Fund acquired an aggregate of 172,963 Shares in open market transactions. The Reporting Persons expended an aggregate of approximately $476,285 (inclusive of commissions paid in connection with such transactions) to acquire the 172,963 Shares acquired in open market purchases on May 16, 2024.

     

    On May 17, 2024, BCM Fund acquired an aggregate of 2 Shares in open market transactions. The Reporting Persons expended an aggregate of approximately $105 (inclusive of commissions paid in connection with such transactions) to acquire the 2 Shares acquired in open market purchases on May 17, 2024.

     

    The purchases on May 16, 2024 and May 17, 2024 were made out of the working capital of BCM Fund. No part of the aggregate purchase price is or will be represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the securities.

     

    ITEM 5.INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5(a) and (b) of the Statement is hereby amended in its entirety to read as follows:

     

    (a) and (b)

     

    All percentages of Shares outstanding contained herein are based on 1,754,795 Shares outstanding as of March 19, 2024, as disclosed in the Annual Report on Form 10-K filed by the Issuer with the SEC on April 1, 2024.

     

    As of the date hereof:

     

    (i)BCM Fund holds of record 322,236 Shares, representing approximately 18.36% of the Shares outstanding. Due to the relationships described in Item 2 above, BCM Fund may be deemed to share voting and investment power with B.Side Management, Mr. Costa and Mr. Mattos with respect to all 322,236 Shares.

     

    (ii)Due to the relationships described in Item 2 above, B.Side Management may be deemed to share voting and investment power with BCM Fund, Mr. Costa and Mr. Mattos with respect to all 322,236 Shares disclosed as beneficially owned by the Reporting Persons herein, representing approximately 18.36% of the Shares outstanding.

     

    (iii)Due to the relationships described in Item 2 above, Mr. Costa may be deemed to share voting and investment power with BCM Fund, B.Side Management and Mr. Mattos with respect to all 322,236 Shares disclosed as beneficially owned by the Reporting Persons herein, representing approximately 18.36% of the Shares outstanding. Mr. Costa disclaims beneficial ownership in all 322,236 Shares reported herein, except to the extent of his pecuniary interest therein.

     

    6

     

     

    (iv)Due to the relationships described in Item 2 above, Mr. Mattos may be deemed to share voting and investment power with BCM Fund, B.Side Management and Mr. Costa with respect to all 322,236 Shares disclosed as beneficially owned by the Reporting Persons herein, representing approximately 18.36% of the Shares outstanding.

     

    Item 5(c) of the Statement is hereby amended and supplemented by the addition of the following information:

     

    (c)           Schedule I hereto sets forth all transactions with respect to the Shares effected by the Reporting Persons since the filing of the Original Statement. All such transactions were effected in the open market, and per share prices do not include any commissions paid in connection with such transactions.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:    May 21, 2024

     

      BCM Investimentos Fundo de Investimento Multimercado Crédito Privado Investimento no Exterior
       
      By: B.Side Wealth Management Gestão de Recursos Ltda., as Fund Manager
       
      By: /s/ Antonio Costa
        Antonio Costa, CEO
       
      B.Side Wealth Management Gestão de Recursos Ltda.
       
      By: /s/ Antonio Costa
        Antonio Costa, CEO
       
      /s/ Antonio Costa
      Antonio Costa
       
      /s/ Martim Prado Mattos
      Martim Prado Mattos

     

     

     

    SCHEDULE I

     

    Reporting Person  Trade Date  Shares Purchased (Sold)   Price per Share 
    BCM Investimentos Fundo de Investimento Multimercado Crédito Privado Investimento no Exterior (“BCM Fund”)  May 16, 2024   158,007   $2.679 
    BCM Fund  May 16, 2024   9,956   $2.952 
    BCM Fund  May 16, 2024   5,000   $2.980 
    BCM Fund  May 17, 2024   2   $2.200 

     

     

    Get the next $CLVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVR

    DatePrice TargetRatingAnalyst
    12/23/2021$12.00 → $10.00Buy
    Canaccord Genuity
    11/12/2021$13.00 → $12.00Buy
    Canaccord Genuity
    7/27/2021$13.00Buy
    Canaccord Genuity
    7/23/2021Market Perform
    Cowen
    More analyst ratings

    $CLVR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clever Leaves Announces Voluntary Delisting and SEC Deregistration

      TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, today announced that its Board of Directors (the "Board") determined to voluntarily delist its common shares, without par value (the "common shares") and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the "Warrants" and together with the common shares, the "Securities") from The Nasdaq Stock Market LLC ("Nasdaq") and deregister its Securities in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"

      4/26/24 4:10:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Reports Fourth Quarter and Full Year 2023 Results

      - 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023. All financial information is provided in US doll

      4/1/24 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia

      TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds ("Paradise"), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for cultivation across Colombia and Latin America. The two companies have already begun rigorous selection, phenotyping, and agronomic trials of several Paradise varieties at Clever Leaves'

      2/13/24 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Financials

    Live finance-specific insights

    See more
    • Clever Leaves Reports Third Quarter 2023 Results

      - Q3 Revenue Increased 33% Year-Over-Year, Propelled by 135% Year-Over-Year Growth in Cannabinoid Revenue, Along with 6% Year-Over-Year Growth in Non-Cannabinoid Revenue - - Q3 Adjusted EBITDA Improved Year-Over-Year to $(2.6) Million Compared to $(3.7) Million, Reflecting Revenue Growth and Continued Aggressive Expense Reductions - - Cash Balance at October 31, 2023 was $6.2 Million, with $1.9 Million in Subsequent Capital Received from the November Sale of the Company's Remaining Stake in Cansativa - - Updated Full Year 2023 Guidance Reflects Revenue Timing Shifts, Revenue Mix, and Adjusted EBITDA Improvement from Continued Operating Efficiencies - TOCANCIPÁ, C

      11/9/23 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves to Hold Third Quarter 2023 Conference Call on Thursday, November 9, 2023 at 5:00 p.m. ET

      TOCANCIPÁ, Colombia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, will hold a conference call on Thursday, November 9, 2023 at 5:00 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023. The Company will provide its financial results in a press release prior to the conference call. Clever Leaves management will host the conference call, followed by a question-and-answer session. Conference Call Date: Thursday, November 9, 2023Time: 5:00 p.m. Eastern timeToll-free dial-in number: 1-855-238-2333International dial-in number: 1-412-317-5222Confere

      11/2/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Reports Second Quarter 2023 Results

      - Total Revenue Increased 21% Year-Over-Year, Driven by 151% Year-Over-Year Growth in Cannabinoid Revenue - - Continued Expense Reductions Drive Improved Adjusted EBITDA Performance of ($2.1) Million - - July 2023 Sale of Portuguese Processing Assets Added $2.7 Million in Cash Following the End of Q2 - - Reaffirming Previously Announced 2023 Guidance - TOCANCIPÁ, Colombia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, is reporting financial and operating results for the second quarter ended June 30, 2023. All financial information is provided in US dollars unless otherwise in

      8/14/23 4:01:00 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Bcm Investimentos Fundo De Investimento Multimercado Credito Privado Investimento No Exterior claimed ownership of 322,234 shares (SEC Form 3)

      3 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      5/21/24 8:07:09 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hague Henry R Iii sold $563 worth of shares (170 units at $3.31), decreasing direct ownership by 1% to 11,951 units (SEC Form 4)

      4 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      3/12/24 4:50:10 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hague Henry R Iii sold $1,623 worth of shares (411 units at $3.95), decreasing direct ownership by 3% to 12,121 units (SEC Form 4)

      4 - Clever Leaves Holdings Inc. (0001819615) (Issuer)

      2/29/24 4:01:46 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      12/23/21 7:40:56 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      11/12/21 8:49:58 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity initiated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $13.00

      7/27/21 7:11:17 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13D/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/21/24 8:03:23 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Clever Leaves Holdings Inc.

      SC 13D - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/15/24 9:11:49 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13G/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      1/23/24 9:07:27 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    Leadership Updates

    Live Leadership Updates

    See more

    $CLVR
    SEC Filings

    See more
    • Clever Leaves Reminds Shareholders of its Upcoming Annual Meeting on June 2, 2023

      TOCANCIPÁ, Colombia, May 26, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, reminds shareholders that it will hold its 2023 Annual Meeting of Shareholders (the "Annual Meeting") on Friday, June 2, 2023 at 10:00 a.m. Eastern Time. The Annual Meeting will be in a virtual-only format. Clever Leaves reminds investors that its board has recommended that shareholders vote "FOR" the proposal to elect each of the five (5) nominees named in the proxy statement to the Board of Directors, "FOR" the appointment of Marcum LLP as the Company's independent registered public accounting firm to serve as in

      5/26/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Appoints William Muecke to Board of Directors

      BOCA RATON, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced that it has appointed William Muecke to its board of directors, effective March 25, 2022, to fill the vacancy resulting from the previously announced departure of Kyle Detwiler, the Company's current chairman and CEO, effective March 24, 2022. Muecke was also appointed to the board's nominating and governance committee, as well as its compensation committee. Muecke is a co-founder and managing member of Artemis Growth Partners, an impact-focused ESG

      3/17/22 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clever Leaves Announces Leadership Transition Plan

      BOCA RATON, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, today announced a leadership transition plan. Andres Fajardo, currently a director and president of the Company, has been selected to succeed Kyle Detwiler as CEO, effective March 24, 2022. Detwiler will remain CEO until March 24, 2022, to ensure a smooth transition, and he will continue to serve as the Company's Chairman until such date. "Today's leadership changes are the culmination of a succession planning process that our board and Kyle have worked on tog

      2/9/22 7:59:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Clever Leaves Holdings Inc.

      15-12G - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/16/24 4:45:21 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Clever Leaves Holdings Inc.

      EFFECT - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/9/24 12:15:20 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clever Leaves Holdings Inc.

      S-8 POS - Clever Leaves Holdings Inc. (0001819615) (Filer)

      5/6/24 4:15:58 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care